DocWire News Editors

DocwireNews

Myelofibrosis (MF) patients have a high susceptibility to frailty that predicts poor overall survival rates, according to a study presented at the 12th International Congress on Myeloproliferative Neoplasms.&nbsp;In a single-center, retrospective cohort study, researchers assessed 439 MF patients, of which 52% had Primary MF, 35%&nbsp; had Post-Polycythemia Vera or Post-Essential thrombocythemia MF, and 13% had prefibrotic MF (average age, 71, 59% male) who were seen at Princess Margaret Cancer Center (PMCC) between January 2004 and December 2018. The researchers constructed a 35-variable Frailty Index (FI) model to categorize each patient as Fit (FI 0-0.19), Pre-frail (FI 0.2-0.29) or Frail (&gt;0.3) at the time of their initial visit to PMCC.The study&rsquo;s key endpoint events were specified as all-cause mortality or transformation to acute myeloid leukemia (AML). The researchers evaluated the effect of each patient category using a Cox proportional hazards model that measured age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI), Dynamic International Prognostic Scoring System (DIPSS) score, transfusion requiring anemia, and type of driver mutations. Data on driver mutations were available in 401 patients, of which 73% had JAK2 mutation, 18% had CALR mutation, 5% had an MPL mutation, and 3.4% were triple negative. The average follow-up in this study was 2.1 years.The results of the study showed that the presence of a JAK2 driver mutation was notably linked with a higher Frailty Index (FI) compared to other driver mutations. A subset analysis of patients with complete molecular profiling revealed that patients with high risk mutations had significantly higher FI scores on average compared to patients without HMR. The researchers observed that independent factors that predicted poor survival included pre (HR=1.71; 95% CI 1.17 to 2.52), frail status (HR=3.38; 95% CI, 1.86 to 6.14), higher DIPSS risk stratification (HR=2.46; 95% CI, 1.59 to 3.01), and transfusion-requiring anemia (HR=2.04; 95% CI, 1.38 to 3.0).The researchers wrote in their conclusion that: &ldquo;Further research is needed to understand how to modify frailty.&rdquo;Bankar A, et al. Prevalence and Impact of Frailty on Outcomes in Myelofibrosis. Presented at the 12th International Congress on Myeloproliferative Neoplasms; October 24-25, 2019; New York, NY.

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Latest News

Prevalence and Impact of Frailty on Outcomes in Myelofibrosis

MPN Conference Coverage 2019

Myelofibrosis (MF) patients have a high susceptibility to frailty that predicts poor overall survival rates, according to a study presented at the 12th International Congress ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe